Alzheimer’s disease remains the most common form of dementia worldwide, and while much research has focused on amyloid plaques and tau tangles, a growing body of evidence points to neuroinflammation as a central engine of disease progression. At the heart of this process are microglia, the brain’s native immune sentinels. In healthy tissue, microglia patrol the brain, clear debris, and support neuronal function. In Alzheimer’s disease, however, they become reactive, releasing a storm of pro-inflammatory signaling molecules such as tumor necrosis factor-alpha, interleukin-6, and interleukin-1 beta that can injure the very neurons they are meant to protect. Understanding what tips microglia into this destructive mode has become one of the most urgent questions in neurodegeneration research.

Phospholipid scramblase 1 has previously been implicated in promoting inflammatory responses in other contexts, which prompted the authors, Lixiang Gao of the Department of Neurology at Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University and Yuejun Lin of the Department of Neurology at Yantaishan Hospital Affiliated to Shandong Medical and Pharmaceutical University, to investigate whether the protein contributes to the pathogenesis of Alzheimer’s disease. Their strategy combined animal and cell-based approaches. In vivo, they used APP/PS1 transgenic mice, a widely used model that develops amyloid pathology and memory deficits, and achieved PLSCR1 knockdown to assess its effects on NLR family pyrin domain containing 3, or NLRP3, inflammasome activation in microglia. In vitro, they turned to BV2 microglial cells stimulated with lipopolysaccharide, a bacterial molecule that reliably provokes inflammatory activation, to dissect the effects of PLSCR1 on cell viability and inflammatory signaling.

The first key observation was that PLSCR1 expression was markedly upregulated in the hippocampus of APP/PS1 mice, the brain region most critical for forming new memories and one of the earliest areas affected in Alzheimer’s disease. The same elevation appeared in LPS-induced BV2 microglial cells, suggesting that PLSCR1 induction is a consistent feature of the inflammatory state that characterizes the disease in both living brain tissue and isolated immune cells. This pattern positioned PLSCR1 not as a passive bystander but as a candidate driver of the neuroinflammatory process, prompting the team to ask what happens when the protein is removed from the equation.

The answer was striking. PLSCR1 knockdown improved cognitive dysfunction in the APP/PS1 mice, indicating that dampening this single protein translated into measurable functional benefits for the animals. Behind that behavioral improvement lay a broad remodeling of the inflammatory environment. When PLSCR1 was silenced, expression of the pro-inflammatory mediators TNF-alpha, iNOS, IL-6, and IL-1 beta went down, while expression of anti-inflammatory and repair-associated markers, including ARG-1, CD206, IL-10, IL-13, and IL-4, went up. In effect, the balance of microglial activity shifted away from a damage-promoting phenotype and toward a restorative one, the kind of polarization that supports tissue healing rather than chronic injury.

The cell culture experiments reinforced this picture and clarified the mechanism. Exposure to lipopolysaccharide promoted microglial activity in the BV2 cells, but PLSCR1 knockdown attenuated that activation and counteracted the LPS-induced shift of microglia toward a pro-inflammatory phenotype. In other words, even when the cells were bombarded with a potent inflammatory trigger, removing PLSCR1 kept them from fully committing to the aggressive state. This suggests that PLSCR1 acts upstream of or in parallel with external inflammatory signals, functioning as a kind of permission factor that allows microglia to escalate their response. Blocking that permission, the data imply, can restrain the escalation itself.

Central to the study’s conclusions is the NLRP3 inflammasome, a multiprotein complex assembled within immune cells that acts as a molecular alarm and munitions factory. When activated, NLRP3 initiates a cascade that processes interleukin-1 beta and related cytokines into their mature, highly inflammatory forms, and its chronic activation has been repeatedly linked to neurodegeneration. The researchers found that PLSCR1 knockdown suppressed NLRP3 inflammasome activation in microglia both in vivo and in vitro, providing a mechanistic thread that connects the protein to the production of interleukin-1 beta and, ultimately, to the cognitive decline observed in the mice. By closing this pathway, PLSCR1 silencing appeared to cut the inflammatory cascade off at a critical junction.

The implications for Alzheimer’s therapy are intriguing, though the authors frame the work as identifying a target rather than delivering a treatment. Current approaches to the disease, including amyloid-targeting antibodies, address upstream pathology but do not directly resolve the neuroinflammatory component that many researchers believe drives ongoing neuronal loss. A strategy that restrains microglial activation through PLSCR1 or the NLRP3 inflammasome could, in principle, complement plaque-directed therapies by protecting the brain’s vulnerable circuits from collateral inflammatory damage. The findings also raise the possibility that PLSCR1 levels could serve as a biomarker of inflammatory activity in the Alzheimer’s brain, helping clinicians track disease state or treatment response.

As with any preclinical study, important steps remain before these results can inform human medicine. The experiments were conducted in a transgenic mouse model and in a microglial cell line, and the complexity of human Alzheimer’s disease, in which inflammation interacts with vascular, metabolic, and genetic factors over decades, may present additional layers of regulation not captured here. Nevertheless, the study delivers a clear and internally consistent message: PLSCR1 functions as a key driver of neuroinflammation and cognitive decline in Alzheimer’s disease, operating through activation of the NLRP3 inflammasome in microglia. By demonstrating that reducing PLSCR1 improves cognition while simultaneously lowering inflammatory cytokines, promoting repair-associated microglial markers, and suppressing inflammasome signaling, Gao and Lin have added a compelling new node to the growing map of Alzheimer’s neuroimmunology, and one that researchers studying inflammasome-targeted therapies will be watching closely.

Subject of Research: The role of PLSCR1 in microglial NLRP3 inflammasome activation and neuroinflammation in Alzheimer's disease

Article Title: PLSCR1 knockdown reduces inflammatory microglial activation in Alzheimer’s disease by inhibiting NLRP3 inflammasome

Article References: Gao, L., & Lin, Y. (2026). PLSCR1 knockdown reduces inflammatory microglial activation in Alzheimer’s disease by inhibiting NLRP3 inflammasome. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01045-y

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01045-y

Keywords: Alzheimer's disease, PLSCR1, microglia, NLRP3 inflammasome, neuroinflammation, cognitive decline, APP/PS1 mice, BV2 cells, interleukin-1 beta, neurodegeneration, knockdown, reduces

Alzheimer’s disease is the most common cause of dementia, characterized by a slow, relentless loss of memory and cognition that accompanies the accumulation of amyloid-beta peptide in the brain, the death of neurons, and the formation of tangled proteins inside cells. Although decades of research have focused on amyloid itself, the upstream molecular switches that determine whether neurons resist or succumb to these insults remain only partly understood. The new work zeroes in on one such switch: a regulatory axis connecting a long non-coding RNA, a microRNA called miR-150, and the WNT/beta-catenin pathway, a signaling system long implicated in cell survival and brain maintenance.

Long non-coding RNAs, or lncRNAs, are transcripts longer than 200 nucleotides that are not translated into proteins. Once dismissed as transcriptional noise, they are now recognized as master regulators of gene expression, capable of sponging up microRNAs, guiding protein complexes to DNA, and modulating signaling pathways. In cancer research, lncRNAs that interact with the WNT/beta-catenin pathway have been extensively characterized, but their roles in neurodegeneration are far less explored. The team behind the new study set out to determine whether one particular lncRNA, Loc646329, might influence the course of Alzheimer’s disease.

The researchers began where many modern investigations do: with publicly available human sequencing data. By analyzing datasets of brain samples from Alzheimer’s patients and healthy controls, they examined how Loc646329 and miR-150 behave in the diseased brain. The datasets, including the publicly archived GSE63501 and GSE67333 series, provided the initial evidence that these two RNA molecules are implicated in the disease state, motivating the laboratory experiments that followed.

To test the mechanism directly, the team turned to SH-SY5Y cells, a human neuroblastoma cell line widely used to model neuronal biology. Fluorescence in situ hybridization revealed that Loc646329 resides predominantly in the cytoplasm, the cellular compartment where a lncRNA would need to be if it were to interact with microRNAs. Two complementary techniques then established the physical link: AGO2-RNA immunoprecipitation, which captures RNA molecules bound to the Argonaute 2 protein at the heart of the microRNA silencing machinery, and dual-luciferase reporter assays, which confirmed that miR-150 directly targets Loc646329. Together, these experiments painted a picture of Loc646329 as a competing endogenous RNA, or molecular sponge, that sequesters miR-150 and prevents it from dampening downstream targets.

The functional consequences of this interaction were tested under brutal conditions: the cells were exposed to aggregated amyloid-beta 1-42, the toxic peptide that accumulates in Alzheimer’s brains. When Loc646329 was overexpressed, the cells fared measurably better. A battery of assays told a consistent story. CCK-8 assays showed improved metabolic viability. EdU incorporation revealed that more cells retained proliferative capacity. Annexin V-FITC/PI flow cytometry and TUNEL staining, two independent measures of programmed cell death, both showed reduced apoptosis. In other words, raising the levels of this single non-coding RNA helped neurons withstand an otherwise lethal amyloid assault.

The mechanistic core of the study lies in what happens downstream of miR-150. The WNT/beta-catenin pathway is a major regulator of neuronal survival, and its dysfunction has been repeatedly linked to Alzheimer’s disease. A key player in this pathway is GSK3beta, an enzyme whose phosphorylation status determines whether beta-catenin, the pathway’s central messenger, is stabilized and allowed to travel to the nucleus to switch on survival genes, or is tagged for destruction. The researchers found that Loc646329 overexpression increased GSK3beta phosphorylation and stabilized beta-catenin, effectively turning up the volume on WNT signaling. Critically, when the team introduced synthetic miR-150 mimics into the cells, the protective effects of Loc646329 on these signaling events were blunted, indicating that the lncRNA’s benefits depend at least partly on its ability to neutralize miR-150.

Cell culture findings, however compelling, are only a prelude to the real test: does this matter in a living brain? To find out, the researchers used APP/PS1 mice, a transgenic strain that carries human amyloid precursor protein and presenilin mutations and progressively develops amyloid plaques and memory deficits resembling Alzheimer’s disease. Using stereotaxic injection, a surgical technique that allows precise delivery of material into defined brain regions, the team introduced an adeno-associated virus carrying the Loc646329 gene directly into the animals’ hippocampus, the brain structure essential for forming new memories.

The results were striking. In the Morris water maze, a standard behavioral test in which mice must learn the location of a hidden platform using spatial cues, the treated animals found the platform more efficiently than their untreated counterparts, demonstrating improved spatial learning and memory. Biochemical and histological analysis revealed the molecular underpinnings of this improvement: the treated mice had a reduced burden of amyloid-beta plaques and increased activation of beta-catenin in the injected brain region. The study thus connected the molecular sponge hypothesis to meaningful outcomes in an intact, diseased brain, a translation that many non-coding RNA studies never achieve.

The authors are careful to frame these findings as preclinical evidence rather than a therapeutic breakthrough. The work was conducted in cell lines and in a single mouse model, and the researchers themselves note that validation in primary neurons, human-derived neuronal models, and clinical samples is required before Loc646329’s therapeutic relevance can be established. delivering RNA-based therapies to the human brain remains a formidable challenge, and microRNA networks are notoriously context-dependent, with the same microRNA sometimes producing different effects in different cell types. Nevertheless, the study adds a compelling new name to the growing roster of non-coding RNAs implicated in Alzheimer’s disease, and it strengthens the case that the WNT/beta-catenin pathway is a druggable node worth pursuing. If subsequent studies confirm that boosting Loc646329 or blocking miR-150 can safely protect human neurons, the humble sponge molecule could one day inform entirely new strategies against a disease that currently has no cure.

Subject of Research: The role of the long non-coding RNA Loc646329 in regulating Alzheimer's disease-related pathology through the miR-150/WNT/beta-catenin signaling axis.

Article Title: LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models

Article References: Abdi, K., Amiri, M., Asadalizadeh, M., Khanmirzaei, A., Javanmard, A.-R., Rezaeimirghaed, O., Hajiesmaeili, M., & Ghaderian, S. M. H. (2026). LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models. Molecular Biology Reports, 53(1), Article 1594. https://doi.org/10.1007/s11033-026-12734-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12734-6

Keywords: Alzheimer's disease, lncRNA Loc646329, miR-150, WNT/beta-catenin signaling, neurodegeneration, amyloid-beta, neuronal apoptosis, APP/PS1 mice, non-coding RNA, hippocampus, gene regulation, GSK3beta phosphorylation